Subscribe
rocky89
rocky89 / iStockphoto.com
10 January 2018Big Pharma

Allergan tries to escape Restasis IPRs

Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit orders stay of PTAB’s Restasis proceedings
29 March 2018   The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.
Americas
Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs
19 January 2018   Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
PTAB dismisses Native American tribe information request
8 January 2018   The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Federal Circuit orders stay of PTAB’s Restasis proceedings
29 March 2018   The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.
Americas
Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs
19 January 2018   Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
PTAB dismisses Native American tribe information request
8 January 2018   The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.

More on this story

Americas
Federal Circuit orders stay of PTAB’s Restasis proceedings
29 March 2018   The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.
Americas
Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs
19 January 2018   Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
PTAB dismisses Native American tribe information request
8 January 2018   The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB